I am reading a case about an employee stock purchase plan (ESPP, sometimes pronounced “espee”).
An ESPP allows employees to buy company stock at a discount. Generally speaking, there is a recurring deduction from payroll, and the at set times during the year - quarterly, semiannually - the company will use the money set aside to buy employer stock on the employee’s behalf.
Up to this point we are not seeing any employee benefit other than convenience.
The employee benefit is that there is a discount on the employee purchase of stock - usually 15%.
Normally this would be a taxable event, as your employer is giving you something for less than fair market value. An ESPP however is an exception to the general rule. You will not owe tax when you purchase the stock. The IRS will step in line and wait for you to sell it.
To make the taxes work best on an ESPP you want to do two things:
(1) Hold the stock for at least two years after the grant date of the ESPP, and
(2) Hold the stock for at least one year after you buy the shares.
The one-year rule is recognizable, as you are angling for long-term capital gains. The two-year is a rule specific to an ESPP.
If you meet the two requirements, then a subsequent sale is considered “qualified.” Fail one or both and the sale will be considered “nonqualified.” The taxation is different depending whether the sale is qualified or not. We will discuss only qualified sales today.
The taxation of a qualified ESPP sale is daft, as it will normally have two pieces:
(1) An ordinary income piece, and
(2) A capital gain piece.
Let’s go through an example to make sense of this.
(1) Ja’Marr was granted 100 shares of ESPP stock at $85.
(2) Assuming the customary 15% discount, Ja’maar bought the stock at $72.25 ($85 minus ($85 times 15%).
(3) Ja’Marr exercised the ESPP when the stock FMV was $95.
(4) He waited the minimum one- and -two-year periods.
(5) He then sold the stock for $100/share.
Ja’Maar has a gain of $2,775 (sold 100 shares at $100 with cost of $72.25).
The gain is carved into two pieces:
(1) The discount piece of $1,275 (100 shares times ($85 minus $72.25) is reported as ordinary income, and
(2) The balance of $1,500 ($2,775 minus $1,275) is reported as long-term capital gain.
Notice what has happened here.
(1) There are two pieces to ESPP taxation: the ordinary piece and the capital gains piece. You may consider it one sale, but it is sliced up and reported in two different places.
(2) The 15% discount is based on the grant date, not the exercise date. The tax Code wants to tax that 15% as ordinary income (think of it as compensation income but without FICA).
(3) The spread between the grant date FMV and exercise date FMV potentially becomes capital gain. You are probably counting on this gain when you exercise the ESPP, and it is a rare benevolence from the tax Code.
Here is the thing about Ja’Marr’s ESPP gain: his employer MAY put the ordinary portion of the gain on his W-2. Or it may not, as there is no requirement for the employer to do anything. Different employers will report ESPPs to their employees differently.
COMMENT: In my experience, nonqualified sales are more likely to wind up on a W-2 than qualified sales. Even that has to be tempered by noting that not every employer does so, and not necessarily for every sale.
This means that a tax preparer may not immediately know that a client has sold an ESPP. Perhaps there is something on the W-2; perhaps not. Maybe the employer sent the employee a letter; maybe not. Perhaps the client alerted the preparer; perhaps not. Maybe the preparer spotted the sale of employer stock on a brokers’ statement; maybe … well, you get the idea.
And there might be no employer to report. Someone could exercise an ESPP, retain the stock and later change jobs. He/she is no longer an employee of the former employer, and the new employer has nothing to do with the matter.
There is a wild west vibe to an ESPP.
By contrast, the reporting of incentive stock options (ISO) to an employee is cleaner. There is a unique W-2 code to use for ISOs (code “V”). If I see that code on a W-2, I immediately know there has been an ISO transaction.
Second, it would be nice to have this tax form:

It is a specialized form, and it is issued when the ESPP is exercised. The tax preparer hopefully keeps a copy in permanent file, pending the day the stock is sold.
Why?
Because Form 3922 tells the preparer what the discount is.
COMMENT: It is my experience that preparers are … so-so … in obtaining and retaining Forms 3922.
What happens if a preparer does not recognize the sale of ESPP stock? It should be on a brokers statement, so the sale is likely reported on the tax return. I expect the 15% discount was never be separated and reported as ordinary income, however. The gain would be taxed, but the IRS might be shorted the difference between one’s ordinary tax rate and capital gains rate.
Let’s look at our case.
Anthony Moiseshyn (AM) worked for Medtronic. As a work benefit, he participated in their ESPP from 2015 through 2020, purchasing their stock at a 15% discount. In 2021 he sold his Medtronic stock for $99,805. His tax preparer, believing that the sale was already included on his W-2, did not report the sale of stock anywhere on the joint individual tax return.
The IRS easily caught this via matching, proposed an adjustment and we now find ourselves discussing a Tax Court case.
AM argued that the sale was already on his W-2.
Show us, replied the IRS.
AM was paid sales commissions in addition to his salary, so his W-2 amount was not as easy as multiplying his semimonthly salary times 24 pay periods. AM also did not keep pay stubs, so he asked Medtronic for copies. There was unfortunately no help coming from that direction.
You have shown us nothing so far, remarked the IRS.
He then presented Fidelity tax reporting materials (Fidelity had executed the trade) explain that “ESPP income will usually be included with … other compensation in [W-2] Box 1.”
That is a true statement, answered the IRS, but Fidelity is not your employer. Medtronic is. Additionally, their word “usually” does not mean your ESPP income was “actually” included in your W-2.
Nothing back yet from Medtronic. Maybe AM can obtain a letter from payroll confirming the amount included on his W-2 or at least provide a contact who can address his claim.
AM explained how Medtronic and Fidelity had each pointed to the other when time came to report the ESPP. He lamented how he felt “kind of caught in the middle.”
I share AM’s frustration. The finger-pointing is not uncommon.
I am especially annoyed by AM’s tax preparer, whom I consider unqualified. I understand the fog of stress, the stupor of exhaustion and the possibility of sheer human error, but there are two items here that should not have gotten past a professional preparer:
(1) Expecting 100% of an ESPP gain to be reported on a W-2
Could it happen? Anything can happen, but experience and judgement say this is very unlikely. The entirety of an incentive stock option trade might be included on a W-2, but an ESPP trade is not reported this way. My first thought was that the preparer was conflating ISO reporting with ESPP reporting, and but even that would be for one type of ISO sale (a fully cashless exercise).
(2) Omitting a Schedule D
This is basic: the IRS will match the brokers 1099 to the individual tax return. Fail to attach a schedule D and the IRS has no latch to match. You may as well pencil-in the IRS notice.
BTW sometimes the preparer will include a form (or line on a form) with the express intent of proving a landing spot for an IRS match, even if the line (or form) is not otherwise required. We tax nerds refer to this as a “coat hanger.”
The Court found AM believable, but that was not enough to prove his argument. The Court concluded :
We are not convinced that the gain from the disposition of … Medtronic ESPP stock was included in the wages reported on his 2021 Form W-2.”
AM lost the case, but I believe the IRS was right. I greatly doubt his ESPP was on his return, and the IRS adjustment was necessary to report the gain.
Our case this week was Moiseshyn v Commissioner, T.C. Memo 2026-114.




